Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Merck & Co., Inc. — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.03 (market cap $378.77M), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 927.4× JPMorgan Diversified Return International Eqty ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and Merck & Co., Inc. for 98 Days on average.
| JPIN | MRK | |
|---|---|---|
Market Cap | $378.77M | $351.28B |
Volume | 13,861 | 7,969,665 |
52-Week High | $77.80 | $156.43 |
52-Week Low | $64.96 | $82.49 |
Typical Hold Time | 120 Days | 98 Days |
Sector | — | Health |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $72.875, down 0.09% with bearish technical signals dominating. The ETF shows oversold conditions with RSI readings below 25, while moving averages and oscillators indicate strong selling pressure. Recent analysis highlights JPIN's focus on international value stocks through a smart beta approach.
The ETF faces significant technical headwinds despite oversold conditions. Investors should weigh the bearish momentum against potential value opportunities in international markets, with the upcoming dividend payment in September 2026 providing income consideration.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
